TOKYO, Apr 20 (Pulse News Wire) – PeptiDream Inc. (4587.T) announced today that its partner Astellas Therapeutics (headquartered in Tokyo, Chiyoda Ku) has initiated a phase 1 clinical trial for the selective Type 1 TNF receptor inhibitor drug candidate AK1,940.
Developed through joint research using PeptiDream’s proprietary Peptide Discovery Platform System (PDPS®), the compound shows strong inhibitory activity and high selectivity against Type 1 TNF receptors, demonstrating efficacy in animal models of inflammatory diseases. This collaboration began in March 2016, focusing on creating cyclic peptides via PDPS® technology. Astellas Therapeutics specializes in autoimmune disorders, severe infections, transplantation, kidney diseases, and orthopedic conditions, aligning well with their strategic development goals.
Upon commencement of the trial, PeptiDream received milestone fees (amount undisclosed). Future clinical milestones and royalties based on sales post-commercialization are also part of the agreement. Clinical trial number: jRCT2,071,250,141 Looking ahead, PeptiDream stated that this development is consistent with previously disclosed expectations for the fiscal year ending December 2026, with no anticipated changes to projected performance figures.
Any updates to forecasts will be communicated promptly.
🟢 Confidence: High AI-translated content.